New Antibody-Drug conjugate enters human trials for Hard-to-Treat cancers
NCT ID NCT07362888
First seen Jan 27, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This early-phase study is testing a new drug called ADCE-B05 in 180 people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to find the safest dose and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
-
Monash Health
NOT_YET_RECRUITINGClayton, South Australia, 3165, Australia
-
Peter MacCallum Cancer Centre
NOT_YET_RECRUITINGMelbourne, Victoria, 3000, Australia
-
Scientia Clinical Research
RECRUITINGRandwick, New South Wales, 2031, Australia
-
Southern Oncology Clinical Research Unit
RECRUITINGBedford Park, South Australia, 5042, Australia
-
University Of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Yale University
RECRUITINGNew Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADCE-B05 (an antibody-drug conjugate)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if ADCE-B05 will effectively shrink tumors or improve survival. Side effects are expected and could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.